In This Section:

◄

Case Studies

Clinical publications

Editorials

Guidelines

Radcliffe Content

Review Articles

►

Cardiomyopathy

Welcome to our featured section on cardiomyopathy

Click here to take the CME-accredited courses.

This educational hub pulls together the latest clinical data, guidelines, congress updates as well as original video content and expert interviews on the management of cardiomyopathies. Some of the content on this hub will be CME-accredited and credits will be available when viewed on Radcliffe Medical Education – our dedicated CME portal. Instructions on how to do so are provided with individual videos.

See more ▼

Close X

Recent Videos

Video

ACC 24 Late-Breaker Discussion: The ARISE-HF Trial

Harriette Van Spall, James L Januzzi,

Watch time: 23m 6s

Broadcast

e-SPACE CRM 2024 - Day 2

Antonio Ceriello, Adeera Levin, Ileana L Piña, et al

Broadcast

e-SPACE CRM 2024 - Day 1

Antonio Ceriello, Adeera Levin, Ileana L Piña, et al

AHA 23: Screening for Peripartum Cardiomyopathies Using an AI Enanced Digital Stethoscope

Video

AHA 23: AI Screening for Peripartum Cardiomyopathies

Demilade Adedinsewo,

Watch time: 4m 59s

Video Series

e-SPACE Heart Failure 2023

Stefan Anker, Giuseppe Rosano, Javier de Juan Bagudá, et al

Watch time: 15h 45m 20s (18 videos)

Video

ESC 23: ATTRibute-CM Trial

Julian Gillmore,

Watch time: 4m 39s

Case Studies

Hypertrophic cardiomyopathy as an unexpected mimic of inducible laryngeal obstruction: the case for cardiopulmonary exercise testing in otolaryngology

Wertheim BM, Kapur S, Lakdawala NK, Carroll TL. J Voice 2023;37:97–100.

Effective treatment of hypertrophic cardiomyopathy with left ventricular outflow tract obstruction using a covered stent

Pekas D, Chawda A, Desai N. BMJ Case Rep 2022;15:e250929.

Hypertrophic cardiomyopathy and left ventricular non-compaction cardiomyopathy: two in one

Gabra B, Anavekar NS, Haaf P. Eur Heart J 2023;44:327.

Concerns with patient reported outcome measurement and value claims for therapy response: the case of mavacamten and symptomatic hypertrophic cardiomyopathy (SHCM)

Langley PC. Innov Pharm 2022;13:10.24926/iip.v13i2.4861.

Hypertrophic cardiomyopathy with extreme outflow tract obstruction

Geske JB, Stephens EH, Dearani JA. Eur Heart J 2022;43:4518.

Multimodality imaging of LEOPARD syndrome: myocardial hypertrophy with diffuse coronary artery dilation

Yang D, Wang Y, Lu M. JACC Case Rep 2022;4:1042–8.

Transcatheter mitral intervention relieves dynamic outflow obstruction and reduces cardiac workload in hypertrophic cardiomyopathy

Kimmelstiel C, Everett KD, Jain P, et al. Circ Heart Fail 2022;15:e009171.

Complete resolution of apical hypertrophy and fibrosis: the role of serial cardiovascular magnetic resonance tissue characterization to differentiate hypertrophic cardiomyopathy from myocarditis

Wilson J, Muthumala A, Khanji MY. Eur Heart J 2022;43:1774.

Multimodality imaging and histopathology in a young man presenting with fulminant lymphocytic myocarditis and cardiogenic shock after mRNA-1273 vaccination

Kadwalwala M, Chadha B, Ortoleva J, Joyce M. BMJ Case Rep 2021;14:e246059.

Mutation of the MYL3 gene in a patient with mid-ventricular obstructive hypertrophic cardiomyopathy

Mavilakandy A, Ahamed H. BMJ Case Rep 2022;15:e244573.

Acute-onset heart failure secondary to biventricular non-compaction cardiomyopathy and atrial septal defect in a woman presenting in the seventh decade

Sharma P, Jobanputra Y, Chait R, Ghumman W. BMJ Case Rep 2022;15:e246385.

Clinically suspected myocarditis temporally related to COVID-19 vaccination in adolescents and young adults: suspected myocarditis after COVID-19 vaccination

Truong DT, Dionne A, Muniz JC, et al. Circulation 2022;145:345–56.

A pacemaker red herring and a hypertrophic cardiomyopathy copycat

Raber I, Palmeri NO, Tahir UA, Zimetbaum PJ. Circulation 2022;145:622–5.

Carditis after COVID-19 vaccination with a messenger RNA vaccine and an inactivated virus vaccine : a case–control study

Lai FTT, Li X, Peng K, et al. Ann Intern Med 2022;175:362–70.

'Heart within a heart': echocardiographic assessment of hypertrophic cardiomyopathy

Weerasekare JM, Geske JB. Eur Heart J 2021;42:4775.

Hydroxychloroquine-induced cardiomyopathy accelerated after gastric banding

Lodge FM, Moody WE, Tosounidou S, et al. Lancet 2021;398:1913.

Clinical publications

Entropy of left ventricular late gadolinium enhancement and its prognostic value in hypertrophic cardiomyopathy a new CMR assessment method

Zhao X, Jin F, Wang J, et al. Int J Cardiol 2023;373:134–41.

Efficacy of SGLT2 inhibitors in patients with diabetes and nonobstructive hypertrophic cardiomyopathy

Subramanian M, Sravani V, Krishna SP, et al. Am J Cardiol 2023;188:80–6.

Implications of structural right ventricular involvement in patients with hypertrophic cardiomyopathy

Zhang Y, Zhu Y, Zhang M, et al. Eur Heart J Qual Care Clin Outcomes 2023;9:34–41.

Impact of hospital volume on outcomes of septal myectomy for hypertrophic cardiomyopathy

Holst KA, Schaff HV, Smedira NG, et al. Ann Thorac Surg 2022;114:2131–8.

Detecting regional fibrosis in hypertrophic cardiomyopathy: the utility of myocardial strain based on cardiac magnetic resonance

She J, Zhao S, Chen Y, et al. Acad Radiol 2023;30:230–8.

Clinical features of heart failure in patients with hypertrophic cardiomyopathy in a regional Japanese cohort　― results from the Kochi RYOMA study ―

Miyamoto Y, Kubo T, Ochi Y, et al. Circ J 2022;86:1934–40.

Impact of race and ethnicity on use and outcomes of septal reduction therapies for obstructive hypertrophic cardiomyopathy

Patlolla SH, Schaff HV, Nishimura RA, et al. J Am Heart Assoc 2023;12:e026661.

Automated quantification of abnormal QRS peaks from high‐resolution ECGs predicts late ventricular arrhythmias in hypertrophic cardiomyopathy: a 5‐year prospective multicenter study

Suszko AM, Chakraborty P, Viswanathan K, et al. J Am Heart Assoc 2022;11:e026025.

Identification of transthyretin cardiac amyloidosis among patients previously diagnosed with hypertrophic cardiomyopathy

Rowin EJ, Ruberg FL, Das G, et al. Circ Cardiovasc Imaging 2022;15:e014938.

Is anterior mitral valve leaflet length important in outcome of septal myectomy for obstructive hypertrophic cardiomyopathy?

Lentz Carvalho J, Schaff HV, Nishimura RA, et al. J Thorac Cardiovasc Surg 2023;165:79–87.e1.

Using electronic health record data to improve understanding of the risk of mental disorders in patients diagnosed with hypertrophic cardiomyopathy

Jin K. Eur J Prev Cardiol 2023;30:82–4.

Risk of incident mental disorders in hypertrophic cardiomyopathy: a nationwide propensity-matched study

Park JB, Yun JY, Kim B, et al. Eur J Prev Cardiol 2023;30:85–94.

Effect of beta-blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy

Wheeler MT, Jacoby D, Elliott PM, et al. Eur J Heart Fail 2022; epub ahead of press.

Survival after septal reduction in patients >65 years old with obstructive hypertrophic cardiomyopathy

Mentias A, Smedira NG, Krishnaswamy A, et al. J Am Coll Cardiol 2023;81:105–15.

Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy

Maron MS, Masri A, Choudhury L, et al. J Am Coll Cardiol 2023;81:34–45.

Myocardial activity at (18)F-FAPI PET/CT and risk for sudden cardiac death in hypertrophic cardiomyopathy

Wang L, Wang Y, Wang J, et al. Radiology 2022; epub ahead of press.

Longitudinal cost of septal myectomy versus alcohol septal ablation for hypertrophic cardiomyopathy

Sun D, Schaff HV, Van Houten HK, et al. Mayo Clin Proc 2022;97:1656–63.

Evidence of advanced pulmonary vascular remodeling in obstructive hypertrophic cardiomyopathy with pulmonary hypertension

Maron BA, Kleiner DE, Arons E, et al. Chest 2022; epub ahead of press.

Toward ECG-based analysis of hypertrophic cardiomyopathy: a novel ECG segmentation method for handling abnormalities

Nezamabadi K, Mayfield J, Li P, et al. J Am Med Inform Assoc 2022;29:1879–89.

Magnetique: an interactive web application to explore transcriptome signatures of heart failure

Britto-Borges T, Ludt A, Boileau E, et al. J Transl Med 2022;20:513.

Posterior wall thickness associates with survival following septal myectomy for obstructive hypertrophic cardiomyopathy

Sun D, Schaff HV, Nishimura RA, et al. JACC Heart Fail 2022;10:831–7.

Validation of the Kansas City Cardiomyopathy Questionnaire in symptomatic obstructive hypertrophic cardiomyopathy

Nassif M, Fine JT, Dolan C, et al. JACC Heart Fail 2022;10:531–9.

Outcomes of patients with hypertrophic obstructive cardiomyopathy and pacemaker implanted after alcohol septal ablation

Veselka J, Liebregts M, Cooper R, et al. JACC Cardiovasc Interv 2022;15:1910–7.

Clinical characteristics and prognostic importance of left ventricular apical aneurysms in hypertrophic cardiomyopathy

Lee DZJ, Montazeri M, Bataiosu R, et al. JACC Cardiovasc Imaging 2022;15:1696–711.

Coexistent diabetes is associated with the presence of adverse phenotypic features in patients with hypertrophic cardiomyopathy

Jex N, Chowdhary A, Thirunavukarasu S, et al. Diabetes Care 2022;45:1852–62.

Multinational federated learning approach to train ECG and echocardiogram models for hypertrophic cardiomyopathy detection

Goto S, Solanki D, John JE, et al. Circulation 2022;146:755–69.

Dose-blinded myosin inhibition in patients with obstructive HCM referred for septal reduction therapy: outcomes through 32-weeks

Desai MY, Owens AT, Geske JB, et al. Circulation 2022; epub ahead of press.

Single-nucleus profiling of human dilated and hypertrophic cardiomyopathy

Chaffin M, Papangeli I, Simonson B, et al. Nature 2022;608:174–80.

The prevalence and association of exercise test abnormalities with sudden cardiac death and transplant-free survival in childhood hypertrophic cardiomyopathy

Conway J, Min S, Villa C, et al. Circulation 2022; epub ahead of press.

Natural history of MYH7-related dilated cardiomyopathy

de Frutos F, Ochoa JP, Navarro-Peñalver M, et al. J Am Coll Cardiol 2022;80:1447–61.

Association of pathogenic DNA variants predisposing to cardiomyopathy with cardiovascular disease outcomes and all-cause mortality

Patel AP, Dron JS, Wang M, et al. JAMA Cardiol 2022;7:723–32.

Rare and common genetic variation underlying the risk of hypertrophic cardiomyopathy in a national biobank

Biddinger KJ, Jurgens SJ, Maamari D, et al. JAMA Cardiol 2022;7:715–22.

High-throughput precision phenotyping of left ventricular hypertrophy with cardiovascular deep learning

Duffy G, Cheng PP, Yuan N, et al. JAMA Cardiol 2022;7:386–95.

Percutaneous intramyocardial septal radiofrequency ablation in patients with drug-refractory hypertrophic obstructive cardiomyopathy

Zhou M, Ta S, Hahn RT, et al. JAMA Cardiol 2022;7:529–38.

Muscle LIM protein force-sensing mediates sarcomeric biomechanical signaling in human familial hypertrophic cardiomyopathy

Riaz M, Park J, Sewanan LR, et al. Circulation 2022;145:1238–53.

Association of septal myectomy with quality of life in patients with left ventricular outflow tract obstruction from hypertrophic cardiomyopathy

Desai MY, Tower-Rader A, Szpakowski N, et al. JAMA Netw Open 2022;5:e227293.

Assessment of disease status and treatment response with artificial intelligence−enhanced electrocardiography in obstructive hypertrophic cardiomyopathy

Tison GH, Siontis KC, Abreau S, et al. J Am Coll Cardiol 2022;79:1032–4.

Survival following alcohol septal ablation or septal myectomy for patients with obstructive hypertrophic cardiomyopathy

Cui H, Schaff HV, Wang S, et al. J Am Coll Cardiol 2022;79:1647–55.

Clinical features and natural history of preadolescent nonsyndromic hypertrophic cardiomyopathy

Norrish G, Cleary A, Field E, et al. J Am Coll Cardiol 2022;79:1986–97.

Effects of metoprolol on exercise hemodynamics in patients with obstructive hypertrophic cardiomyopathy

Dybro AM, Rasmussen TB, Nielsen RR, et al. J Am Coll Cardiol 2022;79:1565–75.

Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy

Desai MY, Owens A, Geske JB, et al. J Am Coll Cardiol 2022;80:95¬–108.

Impact of autophagy on prognosis of patients with dilated cardiomyopathy

Kanamori H, Yoshida A, Naruse G, et al. J Am Coll Cardiol 2022;79:789–801.

Long-term cardiovascular outcomes of COVID-19

Xie Y, Xu E, Bowe B, Al-Aly Z. Nat Med 2022;28:583–90.

Hypertensive disorders in women with peripartum cardiomyopathy: insights from the ESC EORP PPCM Registry

Jackson AM, Petrie MC, Frogoudaki A, et al. Eur J Heart Fail 2021;23:2058–69.

Phenotypic expression, natural history, and risk stratification of cardiomyopathy caused by filamin C truncating variants

Gigli M, Stolfo D, Graw SL, et al. Circulation 2021;144:1600–11.

Altered cardiac energetics and mitochondrial dysfunction in hypertrophic cardiomyopathy

Ranjbarvaziri S, Kooiker KB, Ellenberger M, et al. Circulation 2021;144:1714–31.

Association between sarcomeric variants in hypertrophic cardiomyopathy and myocardial oxygenation: insights from a novel oxygen-sensitive cardiovascular magnetic resonance approach

Raman B, Tunnicliffe EM, Chan K, et al. Circulation 2021;144:1656–8.

Effect of mavacamten on echocardiographic features in symptomatic patients with obstructive hypertrophic cardiomyopathy

Hegde SM, Lester SJ, Solomon SD, et al. J Am Coll Cardiol 2021;78:2518–32.

Randomized trial of metoprolol in patients with obstructive hypertrophic cardiomyopathy

Dybro AM, Rasmussen TB, Nielsen RR, et al. J Am Coll Cardiol 2021;78:2505–17.

Acute myocarditis following COVID-19 mRNA vaccination in adults aged 18 years or older

Simone A, Herald J, Chen A, et al. JAMA Intern Med 2021;181:1668–70.

Role of plakophilin-2 expression on exercise-related progression of arrhythmogenic right ventricular cardiomyopathy: a translational study

Cerrone M, Marrón-Liñares GM, van Opbergen CJM, et al. Eur Heart J 2022;43:1251–64.

SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study

Husby A, Hansen JV, Fosbøl E, et al. BMJ 2021;375:e068665.

Myocarditis cases reported after mRNA-Based COVID-19 vaccination in the US from December 2020 to August 2021

Oster ME, Shay DK, Su JR, et al. JAMA 2022;327:331–40.

Prevalence and cumulative risk of familial idiopathic dilated cardiomyopathy

Huggins GS, Kinnamon DD, Haas GJ, et al. JAMA 2022;327:454–63.

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection

Patone M, Mei XW, Handunnetthi L, et al. Nat Med 2022;28:410–22.

Myocarditis after BNT162b2 mRNA vaccine against covid-19 in Israel

Mevorach D, Anis E, Cedar N, et al. N Engl J Med 2021;385:2140–9.

Myocarditis after covid-19 vaccination in a large health care organization

Witberg G, Barda N, Hoss S, et al. N Engl J Med 2021;385:2132–9.

Editorials

Syncope in hypertrophic cardiomyopathy: explaining the unexplained

Geske JB, Siontis KC, Gersh BJ. Int J Cardiol 2023;373:99–100.

High‐resolution ECG for predicting ventricular arrhythmia in hypertrophic cardiomyopathy: another tool in the toolbox

Gehi AK. J Am Heart Assoc 2022;11:e028095.

Composite endpoints in hypertrophic cardiomyopathy: practice, education, research

Ommen SR. JACC Heart Fail 2023;11:42–3.

Mavacamten in obstructive hypertrophic cardiomyopathy – are beta-blockers blocking part of its shine?

Dominguez F, Cabrera E. Eur J Heart Fail 2023; epub ahead of press.

Increased long-term survival after myectomy: is the pendulum swinging again in this 30-year debate?

Maron MS. J Am Coll Cardiol 2023;81:116–8.

Myosin inhibitors: the next generation

Nair A, Xie L, Silva Enciso JE. J Am Coll Cardiol 2023;81:46–8.

Commentary: invasive therapy for hypertrophic obstructive cardiomyopathy: is it time to reexamine the guidelines?

Mazine A, Tam DY, Fremes SE. J Thorac Cardiovasc Surg 2022;164:1511–3.

Commentary: septal reduction therapy: the sooner, the better?

Wei LM. J Thorac Cardiovasc Surg 2022;164:1513–4.

Evolving epidemiology of hypertrophic cardiomyopathy: shifting the focus from instant to lifetime risk awareness

Canepa M, Olivotto I. Circ Heart Fail 2022;15:e009873.

Refining endpoint measures in clinical trials for hypertrophic cardiomyopathy: the emerging role of patient-reported outcomes

Rowin EJ, Maron MS. JACC Heart Fail 2022;10:540–2.

Left ventricular posterior wall in obstructive hypertrophic cardiomyopathy: a neglected issue in clinical management?

de Gregorio C, Luongo A. JACC Heart Fail 2022;10:838–41.

New pacemaker implantation after alcohol septal ablation: how sharp is the double-edged sword?

Pineda AM, Wang A. JACC Cardiovasc Interv 2022;15:1918–20.

Understanding the prognostic significance of left ventricular apical aneurysms in hypertrophic cardiomyopathy

Elliott PM, Lorenzini M. JACC Cardiovasc Imaging 2022;15:1712–4.

Myosin-related dilated cardiomyopathy: another elephant emerges from darkness

Lanfear DE, Reza N. J Am Coll Cardiol 2022;80:1462–4.

Commentary: left heart remodeling with septal myectomy: fibrosis is a relative but not absolute concern

Blitzer D, Weiner SD, Nguyen SN, Takayama H. J Thorac Cardiovasc Surg 2022;163:1837–8.

Commentary: paradoxical increase in areas of myocardial fibrosis following septal myectomy

Nguyen A. J Thorac Cardiovasc Surg 2022;163:1835.

Hypertrophic cardiomyopathy risk scoring for sudden cardiac death in paediatrics, adolescents, and adults: stuck on the puzzle of clinical, imaging, and genetic features

Bianco F, Bucciarelli V. Eur J Prev Cardiol 2022;29:675–7.

Septal reduction strategies in hypertrophic cardiomyopathy—the scalpel, catheter, or wire?

Bataiosu DR, Rakowski H. JAMA Cardiol 2022;7:538–9.

Surgical septal myectomy and alcohol ablation: not equivalent in efficacy or survival

Sherrid MV, Massera D, Swistel DG. J Am Coll Cardiol 2022;79:1656–9.

Cardiac myosin inhibitors for obstructive hypertrophic cardiomyopathy: where are we on the hype cycle?

Ommen SR. J Am Coll Cardiol 2022;80:109–10.

Hypertrophic cardiomyopathy: a problem at any age

Rossano JW, Lin KY. J Am Coll Cardiol 2022;79:1998–2000.

Beta-blockers and exercise hemodynamics in hypertrophic cardiomyopathy

Borlaug BA, Omote K. J Am Coll Cardiol 2022;79:1576–8.

Targeting the cause of obstructive hypertrophic cardiomyopathy

Larkin HD. JAMA 2022;327:2067.

Future role of new negative inotropic agents in the era of established surgical myectomy for symptomatic obstructive hypertrophic cardiomyopathy

Maron BJ, Maron MS, Sherrid MV, Rowin EJ. J Am Heart Assoc 2022;11:e024566.

Cardiac myosin inhibitors as a novel treatment option for obstructive hypertrophic cardiomyopathy: addressing the core of the matter

Masri A, Olivotto I. J Am Heart Assoc 2022;11:e024656.

Guidelines

Syncope in hypertrophic cardiomyopathy (part II): an expert consensus statement on the diagnosis and management

Brignole M, Cecchi F, Anastasakis A, et al. Int J Cardiol 2022; epub ahead of press.

Perioperative implications of the 2020 American Heart Association/American College of Cardiology guidelines for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a focused review

Addis DR, Townsley MM. J Cardiothorac Vasc Anesth 2022;36:2143–53.

Prognostic relevance of a score for identifying diastolic dysfunction according to the 2016 American Society of Echocardiography/European Association of Cardiovascular Imaging recommendations in patients with hypertrophic cardiomyopathy

Saito C, Minami Y, Haruki S, et al. J Am Soc Echocardiogr 2022;35:469–76.

Recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy

Nagueh SF, Phelan D, Abraham T, et al. J Am Soc Echocardiogr 2022;35:533–69.

Validation of the new American College of Cardiology/American Heart Association Guidelines for the risk stratification of sudden cardiac death in a large Mediterranean cohort with hypertrophic cardiomyopathy

Zegkos T, Tziomalos G, Parcharidou D, et al. Hellenic J Cardiol 2022;63:15–21.

Process of care and a practical toolkit for evaluating and managing arrhythmic risk in the cardiogenetic pregnant patient

Cheung CC, Roston TM, Davies B, et al. Can J Cardiol 2021;37:2001–13.

Comparing clinical performance of current implantable cardioverter-defibrillator implantation recommendations in arrhythmogenic right ventricular cardiomyopathy

Bosman LP, Nielsen Gerlach CL, Cadrin-Tourigny J, et al. Europace 2022;24:296–305.

Radcliffe Content

Cardiac Amyloidosis: Everywhere, but Nowhere

Journal of Asian Pacific Society of Cardiology 2024;3:e05

In Cardiogenic Shock, Age is Not Just a Number

Cardiac Failure Review 2024;10:e04.

Red Flags in Acute Myocarditis

Cardiac Failure Review 2024;10:e02.

Multisystem Inflammatory Syndrome in an Adult: A Rare Cause of ST-Segment Elevation MI

Journal of Asian Pacific Society of Cardiology 2023;2:e44.

Explaining the Unexplained: A Practical Approach to Investigating the Cardiac Arrest Survivor

Arrhythmia & Electrophysiology Review 2023;12:e27

Risk Factors for Aortic Dissection

US Cardiology Review 2023;17:e17.

Cardiovascular Involvement in Fabry’s Disease: New Advances in Diagnostic Strategies, Outcome Prediction and Management

Cardiac Failure Review 2023;9:e12.

Contemporary Review of the Management of Left Ventricular Thrombus

Journal of Asian Pacific Society of Cardiology 2023;2:e23.

How Can We Survive the Heart Failure Pandemic Era? Basic Research for Understanding the Pathophysiology of Heart Failure and Development of Novel Therapies

Journal of Asian Pacific Society of Cardiology 2023;2:e15.

Role of Imaging in Cardiomyopathies

Cardiac Failure Review 2023;9:e08.

Rare Presentation of Cardiac Sarcoidosis With Recurrent Large Pericardial Effusion and Stress-induced Cardiomyopathy

Journal of Asian Pacific Society of Cardiology 2022;1:e23.

Imaging in Women with Heart Failure: Sex-specific Characteristics and Current Challenges

Cardiac Failure Review 2022;8:e29.

Chest Pain in the Cancer Patient

European Cardiology Review 2022;17:e15.

Review Articles

Role of cardiac magnetic resonance (CMR) in planning ventricular septal myomectomy in patients with hypertrophic obstructive cardiomyopathy (HOCM)

Alenezi F, Alajmi H, Agarwal R, Zwischenberger BA. J Card Surg 2022;37:4186–9.

The uptake and utility of genetic testing and genetic counseling for hypertrophic cardiomyopathy—a systematic review and meta-analysis

Cirino AL, Harris SL, Murad AM, et al. J Genet Couns 2022;31:1290–305.

Systematic review and meta-analysis of cardiovascular consequences of myocardial bridging in hypertrophic cardiomyopathy

Bruce C, Ubhi N, McKeegan P, Sanders K. Am J Cardiol 2023;188:110–9.

Mavacamten: a novel disease-specific treatment for hypertrophic cardiomyopathy

Capilupi MJ, Frishman WH. Cardiol Rev 2023;31:45–51.

One gene, two modes of inheritance, four diseases: a systematic review of the cardiac manifestation of pathogenic variants in JPH2-encoded junctophilin-2

Parker LE, Kramer RJ, Kaplan S, Landstrom AP. Trends Cardiovasc Med 2023;33:1–10.

Comparison of demographic, clinical, biochemical, and imaging findings in hypertrophic cardiomyopathy prognosis: a network meta-analysis

Georgiopoulos G, Figliozzi S, Pateras K, et al. JACC Heart Fail 2023;11:30–41.

Mavacamten, a first-in-class cardiac myosin inhibitor for obstructive hypertrophic cardiomyopathy

Dalo JD, Weisman ND, White CM. Ann Pharmacother 2022; epub ahead of press.

Mavacamten treatment for hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomized controlled trials

Ismayl M, Abbasi MA, Marar R, et al. Curr Probl Cardiol 2023;48:101429.

Is there referral bias in outcomes of septal myectomy for hypertrophic cardiomyopathy?

Calderon-Rojas R, Nguyen A, Nishimura RA, et al. J Thorac Cardiovasc Surg 2022;164:881–91.

Hypertrophic cardiomyopathy: an up-to-date snapshot of the clinical drug development pipeline

Tamargo J, Tamargo M, Caballero R. Expert Opin Investig Drugs 2022;31:1027–52.

Microvascular dysfunction in hypertrophic cardiomyopathy

Pelliccia F, Cecchi F, Olivotto I, Camici PG. J Clin Med 2022;11:6560.

The role of the submitral apparatus in hypertrophic obstructive cardiomyopathy

Tao J, Duan F, Long J, et al. J Am Soc Echocardiogr 2022; epub ahead of press.

Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis

Antonopoulos AS, Panagiotopoulos I, Kouroutzoglou A, et al. Eur J Heart Fail 2022;24:1677–96.

Athletic activity for patients with hypertrophic cardiomyopathy and other inherited cardiovascular diseases: JACC Focus Seminar 3/4

Semsarian C, Gray B, Haugaa KH, et al. J Am Coll Cardiol 2022;80:1268–83.

Implantable defibrillators in primary prevention of genetic arrhythmias. A shocking choice?

Corrado D, Link MS, Schwartz PJ. Eur Heart J 2022;43:3029–40.

Latent outflow tract obstruction in hypertrophic cardiomyopathy: clinical characteristics and outcomes of septal myectomy

Cui H, Schaff HV, Nishimura RA, et al. J Thorac Cardiovasc Surg 2022;164:1863–9.e1.

Targeting the sarcomere in inherited cardiomyopathies

Lehman SJ, Crocini C, Leinwand LA. Nat Rev Cardiol 2022;19:353–63.

Mavacamten: first approval

Keam SJ. Drugs 2022;82:1127–35.

Pharmacological management of hypertrophic cardiomyopathy: from bench to bedside

Palandri C, Santini L, Argirò A, et al. Drugs 2022;82:889–912.

Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus

Raman B, Bluemke DA, Lüscher TF, Neubauer S. Eur Heart J 2022;43:1157–72.

Hypertrophic cardiomyopathy: new concepts and therapies

Maron BJ, Rowin EJ, Maron MS. Annu Rev Med 2022;73:363–75.

Inflammation and immune response in arrhythmogenic cardiomyopathy: state-of-the-art review

Asatryan B, Asimaki A, Landstrom AP, et al. Circulation 2021;144:1646–55.

Heart failure subtypes and cardiomyopathies in women

DeFilippis EM, Beale A, Martyn T, et al. Circ Res 2022;130:436–54.

The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication

Ning Q, Wu D, Wang X, et al. Signal Transduct Target Ther 2022;7:57.

Associations of race and ethnicity with presentation and outcomes of hypertrophic cardiomyopathy: JACC focus seminar 6/9

Ntusi NAB, Sliwa K. J Am Coll Cardiol 2021;78:2573–9.

Impact of racial and ethnic disparities on patients with dilated cardiomyopathy: JACC focus seminar 7/9

Ntusi NAB, Sliwa K. J Am Coll Cardiol 2021;78:2580–8.

Diagnosis and evaluation of hypertrophic cardiomyopathy: JACC state-of-the-art review

Maron BJ, Desai MY, Nishimura RA, et al. J Am Coll Cardiol 2022;79:372–89.

Management of hypertrophic cardiomyopathy: JACC state-of-the-art review

Maron BJ, Desai MY, Nishimura RA, et al. J Am Coll Cardiol 2022;79:390–414.

Echocardiographic deformation imaging for early detection of genetic cardiomyopathies: JACC review topic of the week

Taha K, Kirkels FP, Teske AJ, et al. J Am Coll Cardiol 2022;79:594–608.

Minor hypertrophic cardiomyopathy genes, major insights into the genetics of cardiomyopathies

Walsh R, Offerhaus JA, Tadros R, Bezzina CR. Nat Rev Cardiol 2022;19:151–67.

Myocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanisms

Heymans S, Cooper LT. Nat Rev Cardiol 2022;19:75–7.

Myocardial revascularization in ischaemic cardiomyopathy: routine practice vs. scientific evidence

De Caterina R, Liga R, Boden WE. Eur Heart J 2022;43:387–90.

The year in cardiovascular medicine 2021: heart failure and cardiomyopathies

Bauersachs J, de Boer RA, Lindenfeld J, Bozkurt B. Eur Heart J 2022;43:367–76.

The contribution of cardiac fatty acid oxidation to diabetic cardiomyopathy severity

Karwi QG, Sun Q, Lopaschuk GD. Cells 2021;10:3259.

Mesenchymal stem cell therapy in diabetic cardiomyopathy

da Silva JS, Gonçalves RGJ, Vasques JF, et al. Cells 2022;11:240.

Hypertrophic cardiomyopathy: a practical approach to guideline directed management

Ommen SR, Semsarian C. Lancet 2021;398:2102–8.